Glutathione in redox homeostasis: Bridging molecular mechanisms, bioavailability constraints, and translational challenges in systemic therapeutics
Abstract
Glutathione (GSH) is a key intracellular thiol and a master regulator of redox homeostasis, playing a vital role in detoxification, mitochondrial function, and cellular signaling. Despite its well-established mechanistic importance, the clinical translation of GSH-based therapies remains hindered by significant pharmacokinetic barriers and inconsistent therapeutic outcomes. This study integrates a systematic review (PRISMA) with scientometric mapping to identify the landscape of glutathione research and address the gaps between fundamental biochemistry and systemic therapeutics. Studies published between 2004 and 2025 were analyzed according to PRISMA guidelines, focusing on redox signaling, delivery strategies, and translational outcomes Scientometric mapping revealed glutathione as a highly connected hub across diverse research areas, specifically bridging oxidative stress, neurodevelopmental disorders (e.g., ASD), and inflammatory conditions. However, the analysis highlights a persistent disconnect while fundamental research focuses on molecular pathways, clinical studies frequently struggle with low oral bioavailability and rapid enzymatic degradation. Advanced delivery systems, such as liposomal, intranasal, and sublingual formulations, may improve glutathione stability and systemic availability; however, evidence that these pharmacokinetic advantages result in clinically meaningful benefits remains limited. Current findings primarily support the mechanistic and…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Preliminary Toxicity Analysis of 3DCRT versus IMRT on the High Dose Arm of the RTOG 0126 Prostate Cancer Trial
- Adaptive Radiotherapy for Head and Neck Cancer: Initial Clinical Outcomes from a Prospective Trial
- American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology
- Motion Management Strategies and Technical Issues Associated with Stereotactic Body Radiotherapy of Thoracic and Upper Abdominal Tumors: A Review from NRG Oncology
- High-dose-rate interstitial brachytherapy as a monotherapy for localized prostate cancer: treatment description and preliminary results of a phase I/II clinical trial
- Highly efficient training, refinement, and validation of a knowledge-based plan quality control system for radiotherapy clinical trials
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.